Les Laboratoires Servier: PharmaVitae Profile

Publication Date	October 2008
Publisher	Datamonitor
Product Type	Report
Pages	127
ISBN Number	not applicable
Product Code	DAT13812

Buy this product or for assistance call +44 20 7060 7474

PDF £3,425.00$5697 | €3833

FAX Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Servier's performance against key rivals in the prescription pharmaceutical sector
Learn how, Coversyl, the company's biggest growth driver over 2001 to 2007 will become its biggest growth resistor during the forecast period
See how Servier's strong position in the French generics industry will become increasingly strategically important

Content

Chapter 1 About This Profile
- Executive Summary
- Quarterly News Update
- Company Introduction
- Company Sales
- Company Financials
- Key Products And Competitors
- Data Sourcing
- Sales Data
- Analyst Consensus
Chapter 2 Executive Summary
- Key Findings
- Prescription Pharmaceutical Sales Performance, 2001-13
- Servier: Pharmavitae Forecasts At A Glance
- Strategic Insight
- Focussed Player
- 1) Small Molecule Portfolio
- 2)For Cardiovascular Indications
- 3) Geographic Focus Avoids Us Competition
  - Servier Is Prepared For A Growing Generics Market
  - French Generics Market To Expand Due To Healthcare Cost Pressures
  - Generic Pricing Will Impact Extent Of Biogaran's Growth
  - Swot Analysis
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats
Chapter 3 Quarterly News Update
- Product Developments
- Deals And Alliances
- Product Deals
- Technology Deals
- M&a Activity
- Company Announcements
- Future Product Milestones
Chapter 4 Company Introduction
- Key Findings
- Background
- Key Corporate Developments
- M&a History
- Limited History Of M&a Prior To Mid-1990s
- Egis Acquisition Opens Door To Row Markets
- Current Corporate Structure
- Branded Pharmaceuticals
- Generic Pharmaceuticals
Chapter 5 Company Sales
- Key Findings
- Prescription Pharmaceutical Sales And Growth Rate Analysis, 2001-13
- Product Analysis
- Product Analysis, 2001-07
- Product Analysis, 2007-13
- Therapy Area Analysis
- Therapy Area Analysis, 2001-07
- Therapy Area Analysis, 2007-13
- Therapy Area Focus, 2001-13
- Geographic Analysis
- Geographic Analysis, 2001-07
- Geographic Analysis, 2007-13
- Geographic Focus, 2001-13
- Launch/Core/Expiry Analysis
- Explanation Of Launch/Core/Expiry Analysis
- Launch Analysis, 2007-13
- Core Analysis, 2007-13
- Expiry Analysis, 2007-13
- Launch/Core/Expiry Configuration, 2007-13
- Molecule Type Analysis
- Molecule Type Analysis, 2001-07
- Molecule Type Analysis, 2007-13
- Externalization Analysis
- Externalization Analysis, 2001-07
- Externalization Analysis, 2007-13
Chapter 6 Company Financials
- Key Findings
- Reconciliation Between Pharmavitae-Formatted Prescription Pharma Sales And Company-Reported Total Sales, 2001-07
Chapter 7 Key Products And Competitors
- Key Findings
- Overview
- Cardiovascular
- Coversyl
- Overview
- Sales Forecast
- Bipreterax
- Overview
- Sales Forecast
- Vastarel
- Overview
- Sales Forecast
- Daflon
- Overview
- Sales Forecast
- Natrilix
- Overview
- Sales Forecast
- Procoralan
- Overview
- Sales Forecast
- Triplion
- Overview
- Sales Forecast
- Hyperium
- Overview
- Sales Forecast
- Endocrine, Metabolic And Genetic Disorders
- Diamicron
- Overview
- Sales Forecast
- Musculoskeletal
- Protelos
- Overview
- Sales Forecast
- Central Nervous System
- Valdoxan
- Overview
- Sales Forecast
- Respiratory
- Pneumorel
- Overview
- Sales Forecast
- Gastroenterology
- Omeprazole
- Overview
- Sales Forecast
Chapter 8 Appendix
- R&d Pipeline
- References
- Abbreviations
- Exchange Rates
List Of Tables
- Table 1: Servier - Pharmavitae Forecasts At A Glance
- Table 2: Servier Key Product Developments, 2008
- Table 3: Servier Product Deals And Alliances, 2008
- Table 4: Servier Technology Deals And Alliances, 2008
- Table 5: Servier M&a Activity, 2008
- Table 6: Servier Company Announcements, 2008
- Table 7: Servier Future Product Milestones, 2008-10
- Table 8: Servier Product Portfolio Overview ($M), 2001-07
- Table 9: Servier Product Portfolio Overview ($M), 2007-13
- Table 10: Servier Product Portfolio Overview ($M), 2001-07
- Table 11: Servier Product Portfolio Overview ($M), 2007-13
- Table 12: Servier Portfolio Overview By Geographic Region ($M), 2001-07
- Table 13: Servier Portfolio Overview By Geographic Region ($M), 2007-13
- Table 14: Servier Launch Portfolio Overview ($M), 2007-13
- Table 15: Servier Core Portfolio Overview ($M), 2007-13
- Table 16: Servier Expiry Portfolio Overview ($M), 2007-13
- Table 17: Servier Portfolio Overview By Molecule Type ($M), 2001-07
- Table 18: Servier Product Portfolio Overview By Molecule Type ($M), 2007-13
- Table 19: Servier Product Portfolio Overview By Source ($M), 2001-07
- Table 20: Servier Product Portfolio Overview By Source ($M), 2007-13
- Table 21: Total Servier Sales By Business Unit ($M), 2001-07
- Table 22: Key Products Overview
- Table 23: Coversyl: Overview
- Table 24: Coversyl: Sales Forecast ($M), 2007-13
- Table 25: Bipreterax: Overview
- Table 26: Bipreterax: Sales Forecast ($M), 2007-13
- Table 27: Vastarel: Overview
- Table 28: Vastarel: Sales Forecast ($M), 2007-13
- Table 29: Daflon: Overview
- Table 30: Daflon: Sales Forecast ($M), 2007-13
- Table 31: Natrilix: Overview
- Table 32: Natrilix: Sales Forecast ($M), 2007-13
- Table 33: Procoralan: Overview
- Table 34: Procoralan: Sales Forecast ($M), 2007-13
- Table 35: Triplion: Overview
- Table 36: Triplion: Sales Forecast ($M), 2007-13
- Table 37: Hyperium: Overview
- Table 38: Hyperium: Sales Forecast ($M), 2007-13
- Table 39: Diamicron: Overview
- Table 40: Diamicron: Sales Forecast ($M), 2007-13
- Table 41: Protelos: Overview
- Table 42: Protelos: Sales Forecast ($M), 2007-13
- Table 43: Valdoxan: Overview
- Table 44: Valdoxan: Sales Forecast ($M), 2007-13
- Table 45: Pneumorel: Overview
- Table 46: Pneumorel: Sales Forecast ($M), 2007-13
- Table 47: Omeprazole: Overview
- Table 48: Omeprazole: Sales Forecast ($M), 2007-13
- Table 49: Servier's R&d Pipeline (Phase I-Registration)
- Table 50: Exchange Rates, 2007
List Of Figures
- Figure 1: Servier Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 2001-13
- Figure 2: Servier Market Positioning, 2001-13
- Figure 3: French Ace Inhibitor Market* In 2007, Market Share By Company And Product Type (%)
- Figure 4: Servier Prescription Pharmaceutical Sales, By Generic Rx And Branded Rx Products ($M), 2001-13
- Figure 5: Servier Swot Analysis
- Figure 6: Servier, Key Corporate Developments
- Figure 7: Servier, Corporate Structure
- Figure 8: Servier Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 2001-13
- Figure 9: Servier Key Sales Growth Driver & Resistors ($M), 2001-07
- Figure 10: Servier Key Sales Growth Drivers & Resistors ($M), 2007-13
- Figure 11: Servier Prescription Pharmaceutical Sales By Therapy Area ($M), 2001-13
- Figure 12: Servier Prescription Pharma Sales By Therapy Area (% Of Total), 2001-13
- Figure 13: Servier Prescription Pharmaceutical Sales By Geographic Region ($M), 2001-13
- Figure 14: Servier Growth Drivers And Resistors By Geographic Region ($M), 2001-07
- Figure 15: Servier Drivers And Resistors By Geographic Region ($M), 2007-13
- Figure 16: Servier Prescription Pharmaceutical Sales By Geographic Region (% Of Total), 2001-13
- Figure 17: French Ace Inhibitor Market* In 2007, Market Share By Company And Product Type (%)
- Figure 18: Servier Launch/Core/Expiry Configuration ($M), 2007-13
- Figure 19: Servier Prescription Pharmaceutical Sales By Molecule Type ($M), 2001-13
- Figure 20: Servier Growth Drivers And Resistors By Molecule Type ($M), 2007-13
- Figure 21: Servier Prescription Pharmaceutical Sales By Source ($M), 2001-13
- Figure 22: Servier Growth Drivers And Resistors By Source ($M), 2001-07
- Figure 23: Servier Growth Drivers And Resistors By Source ($M), 2007-13